OpenAI has announced the launch of a new AI model called “GPT-Rosalind”, which is specifically designed to serve the bioscience sector. This model aims to accelerate the pace of scientific research and drug discovery, and the company intends to expand into developing other specialized models for various fields.
The launch of “GPT-Rosalind” comes in response to the growing need to use artificial intelligence in biological research, as scientists face great difficulty in dealing with huge amounts of data in multiple fields such as genomics, biochemistry, and protein analysis.
This model was named after the British scientist Rosalind Franklin, in recognition of her important contributions to discovering the structure of DNA, which opened new horizons for modern molecular biology.
OpenAI asserts that the new model aims to support researchers in a wide range of tasks, such as compiling available scientific evidence, forming hypotheses, planning experiments, and carrying out complex research tasks that require multiple steps.
The model also enables researchers to query data in various databases, read the latest published scientific research, use advanced research tools, and suggest new experiments that can be conducted.
The model is based on state-of-the-art in-house technology developed by OpenAI, with a particular focus on enhancing scientific reasoning capabilities in areas such as biochemistry and drug discovery.
The company indicates that developing a new drug may take between 10 to 15 years, and that the chance of any drug that enters the clinical trial stage obtaining final approval does not exceed 10%.
It is worth noting that there are more than 300 million people around the world in need of better treatments for rare diseases, which increases the need for tools that can accelerate the early stages of the discovery process.
The use of artificial intelligence tools in this field has witnessed increasing interest from pharmaceutical companies, academic institutions, and biotechnology companies.
OpenAI is collaborating with a number of organizations to integrate this model into research workflows, including Amgen, Moderna, Thermo Fisher Scientific, and others.
To date, drugs developed entirely using AI are still in the early stages, and none have reached phase III clinical trials.
Experts also warn of the potential dangers of misusing these models to design pathogens, which has prompted more than 100 scientists to demand the imposition of stricter controls on sensitive biological data, in order to prevent the use of these models to wage biological wars. (aitnews)
